Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy

British Journal of Surgery

Volumn 101, Issue 8, 2014, Pages 925-938

  Norum, J H ^a,c   Andersen, K ^b   Sorlie T ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INSTITUTE OF CANCER RESEARCH   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CLASSIFICATION; DISEASE MODEL; FEMALE; GENETIC MARKER; GENETICS; HUMAN; MOUSE; MUTATION; NEOPLASM; PROGNOSIS; REVIEW; TUMOR GENE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENES, NEOPLASM; GENETIC MARKERS; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902291680     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9562     Document Type: Review

References (119)

1. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL,. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-2888.
2. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN,. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009; 14: 320-368.
4. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, et al., Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26: 5697-5704.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
6. Perou CM, Sørlie T, Elsen MB, van de Rijn M, Jeffrey SS, Rees CA, et al., Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
7. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10 869-10 874.
8. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
9. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
10. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al., Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100: 10 393-10 398.
11. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al., Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
12. Wennmalm K, Calza S, Ploner A, Hall P, Bjöhle J, Smeds J, et al., Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes. Genes Chromosomes Cancer 2007; 46: 87-97.
13. Sørlie T, Wang Y, Ziao C, Johnsen H, Naume B, Samaha RR, et al., Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
14. Sørlie T., Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40: 2667-2675.
15. Cancer Genome Atlas Network,. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
16. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, et al., Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010; 2: 38ra47.
17. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, et al., Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009; 15: 3654-3662.
18. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al., An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575-589.
19. Creighton CJ,. The molecular profile of luminal B breast cancer. Biologics 2012; 6: 289-297.
20. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al., Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
21. Tran B, Bedard PL,. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13: 221.
22. Sørlie, T., Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2007; 360: 91-114.
23. Prat A, Perou CM,. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
24. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al., The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
25. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR,. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 2010; 4: 255-266.
26. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al., Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-1485.
27. De Summa S, Pinto R, Sambiasi D, Petriella D, Paradiso V, Paradiso A, et al., BRCAness: a deeper insight into basal-like breast tumors. Ann Oncol 2013; 24 (Suppl 8): viii13-viii21.
28. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K, et al., Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876-887.
29. Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, et al., Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011; 64: 937-946.
30. Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, et al., Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544.
31. Cohen AL, Piccolo SR, Cheng L, Soldi R, Han B, Johnson WE, et al., Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Med Genomics 2013; 6: 35.
32. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al., Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
33. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al., Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
34. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
35. Farmer P, Bonnefol H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al., Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24: 4660-4671.
36. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R,. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-212.
37. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al., The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-404.
38. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
39. Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, et al., Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010; 12: R42.
40. Enerly E, Steinfeld I, Kleivi K, Leivonen SK Aure MR, Russness HG, et al., miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011; 6: e16915.
41. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, et al., MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8: R214.
42. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, et al., Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010; 12: R36.
43. Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, et al., Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol 2011; 5: 61-76.
44. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al., Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012; 109: 2802-2807.
45. Buffa FM, Camps C, Snell CE, Gee HE, Sheldon H, Taylor M, et al., MicroRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011; 71: 5635-5645.
46. Buness A, Ruschhaupt M, Kuner R, Tresch A,. Classification across gene expression microarray studies. BMC Bioinformatics 2009; 10: 453.
47. van den Akker EB, Verbruggen B, Heijmans BT, Beekman M, Kok JN, Slagboom PE, et al., Integrating protein-protein interaction networks with gene-gene co-expression networks improves gene signatures for classifying breast cancer metastasis. J Integr Bioinform 2011; 8: 188.
48. Staiger C, Cadot S, Gyorffy B, Wessels LF, Klau GW,. Current composite-feature classification methods do not outperform simple single-genes classifiers in breast cancer prognosis. Front Genet 2013; 4: 289.
49. Yu K, Lee CH, Tan PH, Tan P,. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004; 10: 5508-5517.
50. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, et al., The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011; 117: 1602-1611.
51. Romero A, Prat A, Garcia-Sáenz JA, Del Prado N, Pelayo A, Furiõ V, et al., Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. Clin Transl Oncol 2013; 16: 386-394.
52. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, et al., Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014; 20: 511-521.
53. Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, et al., Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013; 105: 1504-1511.
54. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
55. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
56. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al., Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10 159 cases from 12 studies. PLoS Med 2010; 7: e1000279.
57. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al., Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010; 16: 6100-6110.
58. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al., High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-350.
59. Denkert C, Loibl S, Müller BM, Eldtmann H, Schmitt WD, Elermann W, et al., Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24: 2786-2793.
60. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
61. Polley MY, Leung SC, McShane LM, Go D, Hugh JC, Mastropasqua MG, et al.,; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group. An international Ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-1906.
62. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al., International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656-1664.
63. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al., Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-2790.
64. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al.,; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25: 339-345.
65. Jørgensen CL, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, et al., PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients. Acta Oncol 2013; [Epub ahead of print].
66. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al.,; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
67. Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM,. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 2010; 13: R51.
68. Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C,. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 2001; 115: 709-718.
69. Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, et al., Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 2012; 227: 42-52.
70. Newburger DE, Kashef-Haghighi D, Weng Z, Salari R, Sweeney RT, Brunner AL, et al., Genome evolution during progression to breast cancer. Genome Res 2013; 23: 1097-1108.
71. Merlo LM, Pepper JW, Reid BJ, Maley CC,. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6: 924-935.
72. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al., Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-473.
73. Nowell PC,. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
74. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG,. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219.
75. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
76. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
77. Behbod F, Rosen JM,. Will cancer stem cells provide new therapeutic targets? Carcinogenesis 2005; 26: 703-711.
78. Polyak K., Breast cancer: origins and evolution. J Clin Invest 2007; 117: 3155-3163.
79. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al., Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
80. Shehata M, Teschendorff A, Sharp G, Novcic N, Russell A, Avril S, et al., Phenotypic and functional characterization of the luminal cell hierarchy of the mammary gland. Breast Cancer Res 2012; 14: R134.
81. Ene CI, Fine HA,. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 2011; 20: 695-697.
82. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al., The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807-817.
83. Buchstaller J, McKeever PE, Morrison SJ,. Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell 2012; 21: 240-252.
84. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
85. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al., Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011; 20: 810-817.
86. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al.,; Breast Cancer Working Group of the International Cancer Genome Consortium. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.
87. Shah, SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
88. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, et al., Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012; 482: 529-533.
89. Meacham CE, Morrison SJ,. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328-337.
90. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
91. Marusyk A, Almendro V, Polyak K,. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-334.
92. Longo DL,. Tumor heterogeneity and personalized medicine. N Engl J Med 2012; 366: 956-957.
93. Marjanovic ND, Weinberg RA, Chaffer CL,. Cell plasticity and heterogeneity in cancer. Clin Chem 2012; 59: 168-179.
94. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al., Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
95. Roy S, Gascard P, Dumont N, Zhao J, Pan D, Petrie S, et al., Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci U S A 2013; 110: 4598-4603.
96. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al., Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277.
97. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al., Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 2011; 13: R87.
98. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, et al., Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 2014; 143: 189-201.
99. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, et al., Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009; 3: 469-482.
100. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al., A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13: 3989-3998.
101. Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, et al., Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res 2014; 16: R5.
102. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, et al., Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res 2014; 20: 404-412.
103. Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader C, et al., Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 2012; 133: 595-606.
104. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, et al., Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 2010; 107: 18 115-18 120.
105. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, et al., Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat 2012; 135: 913-922.
106. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al., A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 2013; 73: 4885-4897.
107. Beckhove P, Schütz F, Diel IJ, Solomayer EF, Bastert G, Foerster J, et al., Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer 2003; 105: 444-453.
108. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al., Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17: 1514-1520.
109. Visonneau S, Cesano A, Torosian MH, Miller EJ, Santoli D,. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 1998; 152: 1299-1311.
110. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, et al., Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 2012; 135: 415-432.
111. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al., Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012; 14: R11.
112. du Manoir S, Orsetti B, Bras-Gonçalves R, Nguyen TT, Lasorsa L, Boissière F, et al., Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol 2014; 8: 431-443.
113. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis WJ, et al., Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
114. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al., Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
115. Guy CT, Cardiff RD, Muller WJ,. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
116. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, et al., Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011; 479: 189-193.
117. van Amerongen R, Bowman AN, Nusse R,. Developmental stage and time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 2012; 11: 387-400.
118. Rios AC, Fu NY, Lindeman GJ, Visvader JE,. In situ identification of bipotent stem cells in the mammary gland. Nature 2014; 506: 322-327.
119. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al., Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-735.